Stocks Listing
CVAC

CureVac N.V.

Share
CVAC
$7.95 1.61%Last Updated Sep 30 2022 07:56 PM
1D Low / 1D High
Low:$7.94
High:$8.33
1D
1.61%
5D
1.79 %
30D
23.19 %
BulletPurple
Market Cap
$1,490,362,624
1.12 %
1.5 B
BulletBlue
Volume 1D
170,993
-
171 K
BulletOrange
Circulating Supply
187,466,997 CVAC
187.5 M

Price Chart

1D
5D
1M
6M
YTD
1Y
MAX
About

CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidate against COVID-19; CV7202, a prophylactic mRNA-based vaccine, which is in Phase 1 clinical trial for rabies virus glycoprotein; vaccine for lassa yellow fever; vaccine for respirational syncytial virus; CV7301, a second-generation lipid nanoparticle flu vaccine; and vaccines for rota, malaria, and universal influenza. The company also develops RNA-based cancer immunotherapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CV9202 (BI 1361849), a self-adjuvanting mRNA vaccine that is in Phase 1 clinical trial for non-small cell lung cancer, as well as tumor associated antigens and shared neo-antigens. In addition, it is developing protein-based therapies for Cas9 gene-editing, ocular diseases, and lung respiratory diseases, as well as therapeutic antibodies. The company was founded in 2000 and is headquartered in Tübingen, Germany.

Historical data

1D
5D
1M
6M
1Y
MAX
Day
Open - Close
Low/High
Volume
Market Cap
Show More
Market Status
Opened
NGM
NASDAQ Stock Exchange
USA
Closes in
6 hours, 26 minutes
Working Hours
Mon-Fri, 01:30 PM - 08:00 PM
Timezone
GMT+0